<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: We aimed to determine if use of <z:chebi fb="0" ids="20551">5-aminosalicylates</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) was associated with a reduced risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) in people with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We used the population-based University of Manitoba IBD Epidemiology Database that tracks <z:hpo ids='HP_0000001'>all</z:hpo> health-care visits from 1984 to 2008 of <z:hpo ids='HP_0000001'>all</z:hpo> Manitobans with IBD and <z:hpo ids='HP_0000001'>all</z:hpo> prescription medication use since 1995 </plain></SENT>
<SENT sid="2" pm="."><plain>In 2008, there were 8,744 subjects with IBD (<z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> 4,325, <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> 4,419, females 4,851, males 3,893) </plain></SENT>
<SENT sid="3" pm="."><plain>In study I, we assessed the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> among <z:chebi fb="0" ids="6775">5-ASA</z:chebi> users (≥1 year, ≥5 years of cumulative use) compared with nonusers </plain></SENT>
<SENT sid="4" pm="."><plain>In study II, we assessed a cohort of those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (n=101) diagnosed in 1995-2008, matched to a control cohort by age, sex, disease duration, and disease diagnosis without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (n=303), and logistic analysis was undertaken </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: For study I, the hazard ratio for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> among <z:chebi fb="0" ids="6775">5-ASA</z:chebi> users was 1.04 (95% confidence interval (CI) 0.67-1.62, P=0.87) at ≥1 year of use and 2.01 (95% CI 1.04-3.9, P=0.038) at ≥ 5 years of use with no difference when assessing by diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>Males, but not females, using <z:chebi fb="0" ids="6775">5-ASA</z:chebi> for ≥ 5 years had an increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In study II, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases had similar use of any <z:chebi fb="0" ids="6775">5-ASA</z:chebi> compared with controls for ≥ 1 year of use (1.02, 95% CI 0.60-1.74) or ≥ 5 years (1.96, 95% CI 0.84-4.55), and a similar mean number of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> prescriptions at 10 vs. 11 (P=0.8) and a similar mean number of dose days at 330 vs. 410 (P=0.69) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results support the majority of studies to date that <z:chebi fb="0" ids="6775">5-ASA</z:chebi> is not chemoprophylactic in IBD for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>